Login to Your Account



Deals And M&A NEWS
CEO: A TESTAMENT TO THE TECHNOLOGY PLATFORM

LONDON – Bicycle Therapeutics Ltd. has convinced Astrazeneca plc of the attractions of its novel peptide platform, signing up the pharma in a potential $1 billion discovery and development collaboration in respiratory, cardiovascular and metabolic disorders.

LONDON – U.K. allergy specialist Atopix Therapeutics Ltd. is being acquired by the privately held  Chiesi Farmaceutica SpA, in a milestone-based deal that could exceed €75 million.

Less than two weeks before the start of the ASH annual meeting, Novartis AG nabbed under-the-radar biotech Selexys Pharmaceuticals Corp. for up to $665 million in up-front, acquisition and milestone payments.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: